GW Pharmaceuticals PLC Company Profile (NASDAQ:GWPH)

About GW Pharmaceuticals PLC (NASDAQ:GWPH)

GW Pharmaceuticals PLC logoGW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GWPH
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.89934 billion
  • Outstanding Shares: 25,308,000
Average Prices:
  • 50 Day Moving Avg: $101.86
  • 200 Day Moving Avg: $114.20
  • 52 Week Range: $79.62 - $137.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.89
  • P/E Growth: 0.45
Sales & Book Value:
  • Annual Revenue: $9.9 million
  • Price / Sales: 293.78
  • Book Value: $18.04 per share
  • Price / Book: 6.37
  • EBIDTA: ($157,050,000.00)
  • Net Margins: -1,021.38%
  • Return on Equity: -22.81%
  • Return on Assets: -19.68%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 13.46%
  • Quick Ratio: 13.28%
  • Average Volume: 273,422 shs.
  • Beta: 2.66
  • Short Ratio: 7.34
Frequently Asked Questions for GW Pharmaceuticals PLC (NASDAQ:GWPH)

What is GW Pharmaceuticals PLC's stock symbol?

GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC's earnings last quarter?

GW Pharmaceuticals PLC (NASDAQ:GWPH) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.70) EPS for the quarter, missing the Zacks' consensus estimate of ($1.50) by $0.20. The firm had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The business's revenue was down 23.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) EPS. View GW Pharmaceuticals PLC's Earnings History.

Where is GW Pharmaceuticals PLC's stock going? Where will GW Pharmaceuticals PLC's stock price be in 2017?

8 equities research analysts have issued 12-month price targets for GW Pharmaceuticals PLC's stock. Their forecasts range from $135.00 to $208.00. On average, they anticipate GW Pharmaceuticals PLC's share price to reach $161.71 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC.

What are analysts saying about GW Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/17/2017)
  • 2. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
  • 3. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)

Who are some of GW Pharmaceuticals PLC's key competitors?

Who are GW Pharmaceuticals PLC's key executives?

GW Pharmaceuticals PLC's management team includes the folowing people:

  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director

Who owns GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Rothschild Investment Corp IL (0.08%), US Bancorp DE (0.05%), Woodstock Corp (0.02%), Fox Run Management L.L.C. (0.02%), Aperio Group LLC (0.01%) and Eqis Capital Management Inc. (0.01%). View Institutional Ownership Trends for GW Pharmaceuticals PLC.

Who sold GW Pharmaceuticals PLC stock? Who is selling GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Profit Investment Management LLC, Bank of Montreal Can and US Bancorp DE. View Insider Buying and Selling for GW Pharmaceuticals PLC.

Who bought GW Pharmaceuticals PLC stock? Who is buying GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, Fox Run Management L.L.C., Quantitative Systematic Strategies LLC, Aperio Group LLC, Eqis Capital Management Inc. and Creative Planning. View Insider Buying and Selling for GW Pharmaceuticals PLC.

How do I buy GW Pharmaceuticals PLC stock?

Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC's stock price today?

One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $114.92.

MarketBeat Community Rating for GW Pharmaceuticals PLC (NASDAQ GWPH)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  392
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GW Pharmaceuticals PLC (NASDAQ:GWPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $161.71 (40.72% upside)

Analysts' Ratings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupSet Price TargetBuy$135.00HighView Rating Details
5/9/2017Cantor FitzgeraldReiterated RatingBuy$208.00HighView Rating Details
2/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$185.00N/AView Rating Details
2/6/2017Cowen and CompanySet Price TargetBuy$135.00N/AView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$162.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis Securities LtdUpgradeSell -> HoldN/AView Rating Details
7/18/2016Bank of America CorporationReiterated RatingBuy$153.00N/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 -> $160.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings History by Quarter for GW Pharmaceuticals PLC (NASDAQ GWPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)ViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GW Pharmaceuticals PLC (NASDAQ:GWPH)
2017 EPS Consensus Estimate: ($8.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.80)($1.80)($1.80)
Q2 20171($1.98)($1.98)($1.98)
Q3 20172($2.34)($2.18)($2.26)
Q4 20171($2.49)($2.49)($2.49)
(Data provided by Zacks Investment Research)


Dividend History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No insider trades for this company have been tracked by


Headline Trends for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Latest Headlines for GW Pharmaceuticals PLC (NASDAQ:GWPH)
DateHeadline logoIt Took Just 10 Days for Nevada's Recreational Marijuana Industry to Fall Into a State of Emergency - July 22 at 7:45 PM logoZacks Investment Research Upgrades GW Pharmaceuticals PLC- (GWPH) to "Buy" - July 17 at 11:08 PM logo Brokerages Anticipate GW Pharmaceuticals PLC (NASDAQ:GWPH) Will Post Quarterly Sales of $2.84 Million - July 15 at 8:36 AM logo5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals - July 14 at 8:31 PM logo Brokerages Anticipate GW Pharmaceuticals PLC (NASDAQ:GWPH) Will Post Earnings of -$1.73 Per Share - July 13 at 12:27 PM logoOne FDA About-Face Doesn't Mean an Orphan-Drug Bonanza - July 13 at 1:06 AM logoGet Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free - - July 12 at 8:02 PM logoGet Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free - July 12 at 12:33 PM logoGW Pullback Is A Buy - Seeking Alpha - July 11 at 8:50 PM logoToday's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW Pharmaceuticals - July 11 at 8:50 PM logoPuration Announces $1.2 Million Sales Contract Adding to Existing Cannabis Extraction Business With Expansion Potential to $16 Million Annually - July 11 at 8:50 PM logoZacks Investment Research Downgrades GW Pharmaceuticals PLC (GWPH) to Sell - July 9 at 2:56 PM logoPolitical Risk Increases For Medical Marijuana - Seeking Alpha - July 4 at 4:59 AM logoGW Pharmaceuticals PLC (GWPH) Receives Average Recommendation of "Buy" from Brokerages - July 4 at 12:32 AM logo3 Marijuana Stocks to Buy If You've Never Bought a Marijuana Stock - June 25 at 6:14 PM logoSurprise! Jeff Sessions Wants to Trample States' Rights and Prosecute Medical Marijuana Businesses - June 24 at 5:55 PM logoGW Pharmaceuticals PLC (GWPH) Upgraded to Hold at ValuEngine - June 21 at 10:38 PM logoBiotech Industry Showing Signs of a Revival in 2017: Today's Research on GW Pharmaceuticals and ZIOPHARM Oncology - June 21 at 7:16 PM logoGW Pharmaceuticals PLC (GWPH) Raised to "Hold" at BidaskClub - June 21 at 6:56 PM logoGW Pharmaceuticals PLC (GWPH) Expected to Post Quarterly Sales of $2.84 Million - June 21 at 10:44 AM logoZacks: Analysts Expect GW Pharmaceuticals PLC (GWPH) to Announce -$1.73 Earnings Per Share - June 19 at 12:48 PM logo5 Critical Questions for One of the Biggest Marijuana Stocks on the Market - June 16 at 6:22 PM logoMedical Marijuana Investing Recommendations - Seeking Alpha - June 16 at 12:52 AM logoCannabis Is Todd Hagopian's Top Biotech Sub-Sector - June 15 at 7:50 PM logoGW Pharmaceuticals PLC (GWPH) Stock Rating Upgraded by BidaskClub - June 14 at 8:28 PM logoWill Donald Trump's Attorney General Jeff Sessions Undermine Legal Marijuana? - June 14 at 7:09 PM logoMaxim Group Analysts Give GW Pharmaceuticals PLC- (GWPH) a $135.00 Price Target - June 11 at 8:30 AM logoHow Big Is the Marijuana Stock Opportunity in Cannabidiol? - June 10 at 5:36 PM logoThis Marijuana Stock Darling Crashed 17% in May - June 8 at 6:35 PM logoGW Pharmaceuticals to Present at the Goldman Sachs 38th Annual ... - Nasdaq - June 7 at 5:07 PM logoGW Pharmaceuticals PLC- (GWPH) Given Average Rating of "Buy" by Brokerages - June 7 at 12:44 AM logoZogenix: Could This Be The Greatest Threat to GW Pharmaceuticals? - June 5 at 5:43 PM logoWhich Marijuana Stock Could Be First to $1 Billion in Annual Sales? - June 5 at 10:45 AM logoMarijuana Stock Investors Are Denied! Vermont's Governor Vetoes Recreational Marijuana Bill - June 3 at 5:21 PM logoSchizophrenia Pipeline Therapeutics Development, Drug Profiles and Key Players Market Analysis Report Now Available at - May 31 at 10:35 PM logoGW Pharmaceuticals is Now Oversold (GWPH) - Nasdaq - May 31 at 5:33 PM logoMarijuana News Roundup: Medical Marijuana Could Cost Big Pharma $4 Billion - May 28 at 6:05 PM logoETFs with exposure to GW Pharmaceuticals Plc : May 26, 2017 - May 27 at 5:57 PM logoGW Pharmaceuticals PLC- (GWPH) Earns Buy Rating from Maxim Group - May 25 at 1:21 PM logoAERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI - May 25 at 3:28 AM logoCannabis Drug Halved Convulsions in Company-Funded Epilepsy Test - May 25 at 3:28 AM logoGW Pharma (GWPH) Announces Publication of Epidiolex Study in NEJM - - May 24 at 5:26 PM logoGW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex® (cannabidiol) in The New England Journal of Medicine - May 24 at 5:26 PM logoGW Pharmaceuticals - Cannabis Cannabinoid - Seeking Alpha - May 21 at 8:17 AM logoGW Pharmaceuticals Announces Research & Development Management Appointments - GlobeNewswire (press release) - May 16 at 5:29 PM logoGW Pharmaceuticals PLC- (GWPH) Downgraded to "Sell" at Zacks Investment Research - May 16 at 12:34 AM logoETFs with exposure to GW Pharmaceuticals Plc : May 15, 2017 - May 15 at 5:09 PM logoQ3 2017 EPS Estimates for GW Pharmaceuticals PLC- Cut by Leerink Swann (GWPH) - May 15 at 8:14 AM logoGW Pharmaceuticals PLC- (GWPH) Downgraded by TheStreet - May 15 at 12:02 AM logoGW Pharmaceuticals PLC- (GWPH) Receives Average Rating of "Buy" from Analysts - May 13 at 12:26 AM



GW Pharmaceuticals PLC (GWPH) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff